U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07531121) titled 'ctDNA for Risk Stratification in Melanoma' on March 31.
Brief Summary: This study examines circulating tumor DNA (ctDNA) as a biomarker in patients with primary melanoma, prior to surgical excision. The hypothesis is that ctDNA may be detectable in pre-operative blood samples from patients with high-risk primary melanoma, potentially providing a baseline measurement for future disease monitoring.
Study Start Date: Sept. 10, 2021
Study Type: OBSERVATIONAL
Condition:
Melanoma (Skin Cancer)
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Herlev and Gentofte Hospital
Information provided by (Responsible Party): Magnus Petur B...